Daré Bioscience, Inc. DARE
Regular-session close
After hours · Nov 19, 4:00 PM ET
- YTD
- -76.58%
- 1 year
- -73.57%
5D -0.2392 (-33.71%)
- Market cap
- 8.89M
- Revenue (ttm)
- 2.84M
- Profit margin
- -253.60%
- EPS (ttm)
- -0.61
- Shares out
- 8.70M
- Forward P/E
- -2.35
- YTD return
- -76.58%
- 1-year return
- -73.57%
- 50-day average
- 3.53
- Volume
- 181.07K
- Avg volume
- 250.15K
- Open
- 0.463
- Previous close
- 0.45
- Day's range
- 0.439 – 0.4799
- 52-week range
- 0.415 – 3.78
- Beta
- 1.34
- Analysts
- Buy
- Price target
- 21.33 (+4619.8%)
Key statistics
- 200-day average
- 4.07
- Enterprise value
- 16.85M
- Price / sales
- 9.77
- Free cash flow
- -20.98M
- Total cash
- 16.41M
- Total debt
- 5.83M
- Short % of float
- 0.35%
Fundamental scorecard
7 of 25 checks passed on DARE’s reported financials
7of 25 checks passed
- Value 2 of 5
- Growth 1 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.60 | -0.55 | +0.05 | +8.33% |
| Aug 12, 2024 | Jun 1, 2024 | -0.57 | 1.52 | +2.09 | +366.67% |
| May 14, 2024 | Mar 1, 2024 | -0.72 | -0.84 | -0.12 | -16.67% |
| Mar 28, 2024 | Dec 1, 2023 | -1.44 | -0.72 | +0.72 | +50.00% |
| Nov 9, 2023 | Sep 1, 2023 | -1.20 | -1.08 | +0.12 | +10.00% |
| Aug 10, 2023 | Jun 1, 2023 | -1.20 | -1.20 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 17, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 24, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 16, 2024 | Jones Trading | main | Buy | Buy |
| Aug 14, 2024 | Maxim Group | down | Buy | Hold |
| May 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Daré Bioscience, Inc.
Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- darebioscience.com
News
12 Health Care Stocks Moving In Tuesday's Intraday Session
Daré Bioscience, Inc. (DARE) Q3 2026 Earnings Call Transcript
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Misses Revenue Estimates
12 Health Care Stocks Moving In Monday's After-Market Session Dare Bioscience Q3 EPS $(0.18) Beats $(0.26) Estimate, Sales $47.628K Miss $2.018M Estimate
Daré Bioscience Reports Third Quarter 2026 Financial Results and Highlights Commercial Execution and Pipeline Advancement
Daré Bioscience Receives Approximately $852,000 in Additional Grant Funding
Daré Bioscience to Host Third Quarter 2026 Financial Results and Company Update Conference Call and Webcast on November 16, 2026
Daré Bioscience Releases Next Episode in “CEO Corner” Video Series
Daré Bioscience to Present at Stifel's 2026 Healthcare Conference
Your note
Sign in to keep a note on DARE — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 3.31% | 287,725 | 917.84K | Sep 29, 2024 |
| AMH Equity Ltd. | 1.15% | 100,000 | 319.00K | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.02% | 89,060 | 284.10K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.74% | 64,395 | 205.42K | Sep 29, 2024 |
| State Street Corporation | 0.27% | 23,515 | 75.01K | Sep 29, 2024 |
| Commonwealth Equity Services, LLC | 0.20% | 17,486 | 55.78K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.37% | 205,801 | 656.50K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.91% | 78,984 | 251.96K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.56% | 48,543 | 154.85K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.18% | 15,461 | 49.32K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.14% | 11,774 | 37.56K | Oct 30, 2024 |
| Price (T.Rowe) U.S. Equities Trust | 0.12% | 10,491 | 33.47K | Sep 29, 2024 |
